NCT06537414: An ongoing trial by GlaxoSmithKline
This trial is ongoing. It must report results 2 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06537414 |
|---|---|
| Title | A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 11, 2024 |
| Completion date | May 31, 2027 |
| Required reporting date | May 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |